Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David MacManus

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Neuropsychologia|July 19, 2005
Recollection and familiarity in dense hippocampal amnesia: a case studyLisa Cipolotti, Chris Bird, Tina Good, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 16, 2003
Magnetic resonance spectroscopy of cerebral cortex is normal in hereditary hyperekplexia due to mutations in the GLRA1 geneMarina A J Tijssen, Peter Brown, David MacManus, et al.
Medical Image Computing and Computer-Assisted Intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention|December 9, 2014
A modality-agnostic patch-based technique for lesion filling in multiple sclerosisFerran Prados, Manuel Jorge Cardoso, David MacManus, et al.
Bioengineering (Basel, Switzerland)|April 26, 2025
Computational Modelling of Protected and Unprotected Head Impacts in RugbyThea Hodges, Adam Jones, Lucía Pérez Del Olmo, et al.
The Lancet. Neurology|January 10, 2012
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trialDavid H Miller, Thomas Weber, Richard Grove, et al.
Health Technology Assessment (Winchester, England)|February 14, 2015
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosisSusan Ball, Jane Vickery, Jeremy Hobart, et al.
European Journal of Neurology|October 12, 2023
Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysisAlberto Calvi, Zoe Mendelsohn, Weaam Hamed, et al.
Multiple Sclerosis and Related Disorders|July 11, 2018
A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE studyJulian Gold, Monica Marta, Ute C Meier, et al.
Trials|December 8, 2025
The Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapyGioia Riboni-Verri, Christopher E McMurran, Trisha Mukherjee, et al.
Neurology|March 12, 2022
Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple SclerosisAlberto Calvi, Ferran Prados Carrasco, Carmen Tur, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Neuropsychologia|July 19, 2005
Recollection and familiarity in dense hippocampal amnesia: a case studyLisa Cipolotti, Chris Bird, Tina Good, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 16, 2003
Magnetic resonance spectroscopy of cerebral cortex is normal in hereditary hyperekplexia due to mutations in the GLRA1 geneMarina A J Tijssen, Peter Brown, David MacManus, et al.
Medical Image Computing and Computer-Assisted Intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention|December 9, 2014
A modality-agnostic patch-based technique for lesion filling in multiple sclerosisFerran Prados, Manuel Jorge Cardoso, David MacManus, et al.
Bioengineering (Basel, Switzerland)|April 26, 2025
Computational Modelling of Protected and Unprotected Head Impacts in RugbyThea Hodges, Adam Jones, Lucía Pérez Del Olmo, et al.
The Lancet. Neurology|January 10, 2012
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trialDavid H Miller, Thomas Weber, Richard Grove, et al.
Health Technology Assessment (Winchester, England)|February 14, 2015
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosisSusan Ball, Jane Vickery, Jeremy Hobart, et al.
European Journal of Neurology|October 12, 2023
Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysisAlberto Calvi, Zoe Mendelsohn, Weaam Hamed, et al.
Multiple Sclerosis and Related Disorders|July 11, 2018
A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE studyJulian Gold, Monica Marta, Ute C Meier, et al.
Trials|December 8, 2025
The Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapyGioia Riboni-Verri, Christopher E McMurran, Trisha Mukherjee, et al.
Neurology|March 12, 2022
Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple SclerosisAlberto Calvi, Ferran Prados Carrasco, Carmen Tur, et al.
Pageof 3